Cargando…

Percent free prostate-specific antigen for prostate cancer diagnosis in Chinese men with a PSA of 4.0–10.0 ng/mL: Results from the Chinese Prostate Cancer Consortium

OBJECTIVE: To test the diagnostic performance of percent free prostate-specific antigen (%fPSA) in predicting any prostate cancer (PCa) and high-grade prostate cancer (HGPCa) in a retrospective multi-center biopsy cohort with a PSA level of 4.0–10.0 ng/mL in China. METHODS: Consecutive patients with...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Rui, Xie, Liping, Cai, Xiaobing, Huang, Yiran, Zhou, Liqun, Ma, Lulin, Gao, Xu, Xu, Chuanliang, Ren, Shancheng, Shao, Pengfei, Xu, Danfeng, Xu, Kexin, Ye, Zhangqun, Liu, Chunxiao, Ye, Dingwei, Lu, Li, Fu, Qiang, Hou, Jianquan, Yuan, Jianlin, He, Dalin, Zhou, Tie, Wang, Fubo, He, Biming, Sun, Yinghao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Second Military Medical University 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5730736/
https://www.ncbi.nlm.nih.gov/pubmed/29264128
http://dx.doi.org/10.1016/j.ajur.2015.04.022
Descripción
Sumario:OBJECTIVE: To test the diagnostic performance of percent free prostate-specific antigen (%fPSA) in predicting any prostate cancer (PCa) and high-grade prostate cancer (HGPCa) in a retrospective multi-center biopsy cohort with a PSA level of 4.0–10.0 ng/mL in China. METHODS: Consecutive patients with a PSA of 4.0–10.0 ng/mL who underwent transrectal ultrasound-guided biopsy were enrolled at 16 Chinese medical centers from January 1st, 2010 to December 31st, 2013. Total and free serum PSA determinations were performed using three types of electro-chemiluminescence immunoassays recalibrated to the World Health Organization (WHO) standard. The diagnostic accuracy of PSA, %fPSA, and %fPSA in combination with PSA (%fPSA + PSA) was determined using the area under the receiver operating characteristic (ROC) curve (AUC). RESULTS: A total of 2310 consecutive men with PSA levels between 4.0 and 10.0 ng/mL were included, and the detection rate of PCa was 25.1%. The AUC of %fPSA and %fPSA + PSA in predicting any PCa was superior to PSA alone in men aged ≥60 years (0.623 vs. 0.534, p < 0.0001) but not in men aged 40–59 years (0.517 vs. 0.518, p = 0.939). Similar result was yield in predicting HGPCa. CONCLUSION: In a clinical setting of Chinese men with 4.0–10.0 ng/mL PSA undergoing initial prostate biopsy, adding %fPSA to PSA can moderately improve the diagnostic accuracy for any PCa and HGPCa compared with PSA alone in patients ≥60 but not in patients aged 40–59 years.